The short version of REV-ERB agonist fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-09-05. Anything still debated is marked as such rather than presented as settled.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
=== A10AD Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting === A10AD01 Insulin (human) A10AD02 Insulin (beef) A10AD03 Insulin (pork) A10AD04 Insulin lispro A10AD05 Insulin aspart A10AD06 Insulin degludec and insulin aspart A10AD30 Combinations
According to one cable, Deputy Assistant Secretary of State for European and Eurasian Affairs Matthew Bryza "has been clear with Saakashvili: if Georgia uses force or stumbles into a conflict, Saakashvili will find himself alone, blamed by the international community for recklessness." Tefft was told by an Abkhaz official in 2007 that there had been an attempt by Russia to coerce Abkhaz leader Sergei Bagapsh into launching a military operation against Georgia in 2006. President of France Nicolas Sarkozy assured Putin in October 2007 that France did not support Georgia's NATO membership while telling Saakashvili the opposite. In January 2008, the French government was not enthusiastic about Ukraine's plans to join NATO.
====== Master's degree and Graduate Certificate Programs in Pharmacy Leadership ====== In 2016, the college became the first pharmacy school in the US to offer an online MS degree program and graduate certificate in pharmacy leadership. These programs combine leadership and professional development in health care business and management courses. These are the first programs at the university to be a partnership between three difference colleges:
Sources: en.wikipedia.org
Properties also decrease with the age of the fiber. Younger fibers tend to be stronger and more elastic than older ones. Many natural fibers exhibit strain rate sensitivity due to their viscoelastic nature. Bone contains collagen and exhibits strain rate sensitivity in that the stiffness increases with strain rate, also known as strain hardening. Spider silk has hard and elastic regions that together contribute to its strain rate sensitivity, these cause the silk to exhibit strain hardening as well. Properties of natural fibers are also dependent on the moisture content in the fiber.
=== Development and marketing === Prior to the development of remifentanil, most short-acting hypnotics and amnestics faced issues with prolonged use, where accumulation would result in unfavorable lingering effects during post-operative recovery. Remifentanil was designed to serve as a strong anesthetic with an ultra-short and predictable duration that would not have accumulation issues. Remifentanil was patented by Glaxo Wellcome Inc. and was FDA approved on July 12, 1996. Its patent ended on the 10th of September 2017.
=== Land reform === Segni's appointment seemed to halt Gullo's agrarian reform drive: between September 1946 and December 1947 issued two decrees that allowed landowners to reclaim unimproved lands. This secured the support of southern elites for the Christian Democrat party, enabling it to win the 18 April 1948 general elections. It increased the tension between the two factions and rekindled laborer occupation of uncultivated land. The Massacre of Melissa, took place in Calabria: on 24 October 1949, some 14,000 peasants from Catanzaro and Cosenza, accompanied by women, children and work animals, occupied the large latifundia and began planting. A group of agrarian Calabrian CD parliamentarians went to Rome, protesting and asking Scelba to use force against the peasants. Scelba sent Mobile Units (mechanized riot police), to Calabria, which stopped at Melissa, in Crotone, finding a large number of protesters on the Fragalà estate, owned by Baron Luigi Berlingeri. The land was supposed to be assigned to the municipality, but the Berlingeri family had usurped it. The peasants claimed at least half of it, but the baron was willing to cede only a third. On 29 October 1949, police, after demanding the crowd of peasants to leave, fired at eye level, wounding 15 wounded and killing 3: Giovanni Zito, Francesco Nigro, and Angelina Mauro. This massacre, combined with that of Portella della Ginestra, in Sicily, which took place on 1 May 1947, provoked strikes and peasant demonstrations throughout Italy.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.